Why Is Immunotherapy Losing Momentum? An Invisible Brake on the Surface of T Cells Comes Into View

The central idea behind cancer immunotherapy is to awaken the body’s own defense system, enabling T cells to recognize and attack tumors again. But the clinical reality is often more complicated: some patients respond at first, only for the treatment effect to slowly fade. A new study focuses on a molecule less familiar to the public, SLAMF6, and suggests that it may act like a built-in brake hidden on the surface of T cells, gradually weakening the immune attack during a prolonged struggle.

This study, published in *Nature*, was led by André Veillette’s team at the Montreal Clinical Research Institute. The study indicates that SLAMF6 does not necessarily have to be activated by the same-named molecule on tumor cells. Instead, it can self-engage on the T-cell surface through “homotypic interaction on the same cell,” thereby suppressing T-cell activation. In other words, this brake is not only an obstacle added by the tumor; it may also be part of the T cell’s own structure.

This mechanism matters because it fills in one piece of the puzzle of immunotherapy resistance or failure. Existing immune checkpoint drugs mostly target pathways such as PD-1, PD-L1, or CTLA-4, but not all tumors have durable responses to these treatments. The research team’s data show that SLAMF6 weakens T-cell activation and anti-tumor immunity, and is associated with an increase in exhausted T cells. This exhausted state is precisely the kind of functional decline often seen after immune cells face tumors over a long period.

To test whether this target could be addressed with a drug, the researchers developed monoclonal antibodies against human SLAMF6. According to the *Nature* paper and materials released by the research institution, these antibodies can interfere with SLAMF6 binding to itself, enhance activation of human T cells, and, in mouse cancer models, reduce the proportion of exhausted T cells and inhibit tumor growth. These results make SLAMF6 not only a biological clue, but also a potential drug target for immunotherapy.

However, this is still mainly preclinical evidence. Mouse models and in vitro experiments with human T cells can reveal mechanisms and feasibility, but they cannot be directly equated with treatment efficacy in patients. SLAMF6 is involved in regulating immune cells. If it is blocked for a long period in humans, whether it would cause excessive immune activation, autoimmune risk, or unpredictable interactions with existing immune checkpoint inhibitors will all need to be answered step by step in clinical trials.

The research team said the next goal is to advance this type of antibody into early clinical trials, potentially covering both solid tumors and blood cancers. But which cancers are most likely to benefit, and whether patients should be selected based on SLAMF6 expression, T-cell exhaustion status, or other immune markers, remain unresolved. A subsequent author correction published by *Nature* also added a related reference, noting that abnormal expression of SLAMF6 by acute myeloid leukemia cells may suppress T-cell activation, suggesting that the role of this pathway in different cancers may be more complex than a single model indicates.

The value of this study does not lie in declaring that immunotherapy is about to gain a universal new solution. Rather, it pushes the question of “why T cells stop” one step closer to the cell surface. If SLAMF6 antibodies can eventually prove safe and effective in humans, they may become a strategy to reinforce existing immunotherapies. If the results fall short of expectations, they will still help researchers understand more precisely how anti-cancer immunity is activated, slowed down, and ultimately drained of strength.